Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $231,714.00 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Sharon Benzeno sold 11,034 shares of the business’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $21.00, for a total transaction of $231,714.00. Following the sale, the insider owned 272,751 shares in the company, valued at $5,727,771. The trade was a 3.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sharon Benzeno also recently made the following trade(s):

• On Monday, June 29th, Sharon Benzeno sold 154,768 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $21.14, for a total transaction of $3,271,795.52.

Adaptive Biotechnologies Stock Down 5.3%

Shares of NASDAQ ADPT opened at $21.19 on Friday. The stock has a market capitalization of $3.39 billion, a price-to-earnings ratio of -64.21 and a beta of 2.07. Adaptive Biotechnologies Corporation has a 52 week low of $9.96 and a 52 week high of $22.80. The firm has a 50-day moving average price of $15.95 and a 200 day moving average price of $15.83.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The company had revenue of $70.87 million for the quarter, compared to analyst estimates of $61.03 million. During the same period in the prior year, the business posted ($0.20) earnings per share. The firm’s revenue for the quarter was up 35.1% compared to the same quarter last year. Equities research analysts expect that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Morgan Stanley reduced their price objective on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Guggenheim raised their price target on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Monday. BTIG Research reaffirmed a “buy” rating and set a $22.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday, June 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Monday, April 20th. Finally, TD Cowen raised their target price on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $20.50.

Institutional Trading of Adaptive Biotechnologies

A number of hedge funds have recently bought and sold shares of the company. Ameriprise Financial Inc. raised its holdings in Adaptive Biotechnologies by 84.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after acquiring an additional 2,731,648 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Adaptive Biotechnologies by 303.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock worth $71,252,000 after purchasing an additional 3,299,635 shares during the last quarter. Westfield Capital Management Co. LP acquired a new stake in shares of Adaptive Biotechnologies during the fourth quarter worth $65,942,000. Geode Capital Management LLC grew its position in shares of Adaptive Biotechnologies by 3.3% in the fourth quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock valued at $57,041,000 after purchasing an additional 110,825 shares during the period. Finally, State Street Corp grew its position in shares of Adaptive Biotechnologies by 3.3% in the fourth quarter. State Street Corp now owns 3,181,644 shares of the company’s stock valued at $51,670,000 after purchasing an additional 102,362 shares during the period. Institutional investors and hedge funds own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.